Targeting CDK9: A promising therapeutic opportunity in prostate cancer
Date
2016
Authors
Rahaman, M.H.
Kumarasiri, M.
Mekonnen, L.B.
Yu, M.
Diab, S.
Albrecht, H.
Milne, R.W.
Wang, S.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Endocrine-Related Cancer, 2016; 23(12):T211-T226
Statement of Responsibility
Conference Name
Abstract
Cyclin-dependent kinase 9 (CDK9) is a key transcriptional regulator and a lucrative target for cancer treatment. Targeting CDK9 can effectively confine the hyperactivity of androgen receptor and the constitutive expression of anti-apoptotic proteins; both being main causes of prostate cancer (PCa) development and progression. In castrate-resistant PCa, traditional therapies that only target androgen receptor (AR) have become obsolete due to reprograming in AR activity to make the cells independent of androgen. CDK9 inhibitors may provide a new and better therapeutic opportunity over traditional treatment options by targeting both androgen receptor activity and anti-apoptotic proteins, improving the chances of positive outcomes, especially in patients with the advanced disease. This review focuses on biological functions of CDK9, its involvement with AR and the potential for therapeutic opportunities in PCa treatment.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
Copyright 2016 Society for Endocrinology